# US 2001/0025030 A1 · cDNA for human methylenetetrahydrofolate reductase and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025030 A1
- Document ID: US20010025030A1
- Status: Published application
- Kind: A1
- Application number: 09/728,910
- Filed: 2000-12-01
- Published: 2001-09-27
- Earliest claimed: 1999-03-01
- Inventors: Rima Rozen; Jaspreet Sekhon
- Web page: https://patentgrep.com/patent/US20010025030A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C12N 9/0028: {with NAD or NADP as acceptor (1.5.1)}
- C12Y 105/0102: Methylenetetrahydrofolate reductase [NAD(P)H] (1.5.1.20)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/315: Phosphorothioates
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention features antisense molecules that inhibit the expression of MTHFR. These compounds are useful in the treatment, stabilization, and prevention of various cancers.

## Claims

### Claim 1

A method of treating, stabilizing, or preventing cancer in a mammal, said method comprising administering to or expressing in said mammal a non allele-specific antisense nucleic acid that binds an MTHFR nucleic acid and inhibits MTHFR protein expression in said mammal, said inhibition being sufficient to treat, stabilize, or prevent cancer in said mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cancer is a breast carcinoma, colon carcinoma, colorectal carcinoma, neuroblastoma, or glioma.

### Claim 3 (depends on 1)

The method of claim 1, wherein said antisense nucleic acid binds exon 5 of said MTHFR nucleic acid.

### Claim 4 (depends on 1)

The method of claim 1, wherein said antisense nucleic acid is a phosphorothioate nucleic acid.

### Claim 5 (depends on 1)

The method of claim 1, wherein said antisense nucleic acid is contained in a recombinant viral vector.

### Claim 6 (depends on 1)

The method of claim 1, wherein said antisense nucleic acid is administered intravenously, parenterally, subcutaneously, intramuscularly, intraventricularly, or intraperitoneally.

### Claim 7

A non allele-specific antisense nucleic acid that binds an MTHFR nucleic acid and inhibits MTHFR protein expression in a mammal, said inhibition being sufficient to treat, stabilize, or prevent cancer in said mammal.

### Claim 8 (depends on 7)

The antisense nucleic acid of claim 7, wherein said cancer is a breast carcinoma, colon carcinoma, colorectal carcinoma, neuroblastoma, or glioma.

### Claim 9 (depends on 7)

The antisense nucleic acid of claim 7, wherein said antisense nucleic acid binds exon 5 of said MTHFR nucleic acid.

### Claim 10 (depends on 7)

The antisense nucleic acid of claim 7, wherein said antisense nucleic acid is a phosphorothioate nucleic acid.

### Claim 11

A vector comprising a nucleic acid encoding a non allele-specific antisense nucleic acid that binds an MTHFR nucleic acid and inhibits MTHFR protein expression in a mammal, said inhibition being sufficient to treat, stabilize, or prevent cancer in said mammal.
